Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Last Gasp Or New Life? 2009's Novel Products Have Blockbuster Potential

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers a possible a return of the blockbuster.
Advertisement

Related Content

Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme
Big Pharma's March Into Biotech Could Make Big Biologics A Big '09 Theme
Chart: "Wild Cards: NMEs and New Biologics That Are Still Pending After FDA Missed User Fee Goal Dates In 2008"
The Return Of The Blockbuster? Stage Is Set For Prasugrel Approval
Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval
FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally
Niche, Lackluster: Two Words That Sum Up 2008 NME Launches
PSA: What We Have Here Is A Failure to Innovate
PSA: What We Have Here Is A Failure to Innovate
GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis

Topics

Advertisement
UsernamePublicRestriction

Register

PS004070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel